MR-based Stroke Mechanism and Future Risk Score (MR-STARS)

August 26, 2021 updated by: Xin Lou, Chinese PLA General Hospital
To explore prediction model for outcome of patients with acute ischemic stroke using multimodal Magnetic Resonance(MR) imaging was a multicenter prospective observational study supported by National Natural Science Foundation of China. Imaging evaluation of hemodynamic status and antegrade flow were assessed. Patients were followed up to record radiological and clinical outcome. The study recruited patients from 11 centers located in 10 provinces or province-level municipalities across the northeast to the southeast of China mainland.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Patients:

Patients with cerebral ischemia sympton of onset in 24 hours were included. Baseline materials, NIH stroke scale score, modified Rankin Scale at admission, stroke causes, time from sympton onset to enrollment were recorded.

Imaging scan were conducted at admission, within 7 days after admission.

Imaging protocols:

MRI scan protocols: T2 weighted image, T1 weighted image, Diffusion weighted image(DWI), fluid-attenuated inversion recovery(FLAIR), Perfusion weighted image(PWI), arterial spin labeling(ASL) , susceptibility-weighted imaging(SWI).

Contrast agent:

Omniscan 2ml/kg, Inject rate:3ml/s

Digital subtraction angiography(DSA) protocols:

Selective angiography and imaging phase from arterial phase to late venous phase.

Imaging evaluation:

Antegrade flow assessment from ASL Cerebral blood flow(CBF) map. Collateral flow assessment from ASL CBF map, ASL subtraction CBF map, PWI postprocessing map, FLAIR hyperintensity vascular sign.

Initial infarct volume measurement form DWI. Final infarct volume measurement from FLAIR. DWI-ASPECTS. Stroke lesions pattern assessment identified on DWI. DSA antegrade and collateral grade using modified Thrombolysis in Cerebral Infarction(TICI) scale and The American Society of Interventional and Therapeutic Neuroradiology (ASITN) collateral grading system.

Treatment:

Intravenous recombinant tissue plasminogen activator(rtPA), endovascular therapy and conventional treatment including neuro protection, ante-platelet and statin.

Follow up:

within Seven days and a month after imaging follow up and clinical stroke event and modified Rankin Scale(mRS) record in 1 year.

Note:

The original trial from 2015 to 2018 recruited patients with acute and subacute ischemic stroke, and the trial plan was changed to recruit patients with acute cerebral ischemia sympton of onset within 24 h.The study has been upgraded from a single-center study to a multi-center study since 2018.

Study Type

Observational

Enrollment (Actual)

961

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Beijing
      • Beijing, Beijing, China, 100853
        • Chinese PLA General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Ischemic stroke patients with sympton onset in 24 hours

Description

Inclusion Criteria:

  • age≥18
  • Cerebral ischemic sympton with onset in 24 hours
  • pre mRS<2
  • All MR examination performed according to study protocol
  • Signed informed consent obtained from the patient or patient's legally authorized representative
  • Having complete medical history and clinical follow up
  • Imaging data can be processed

Exclusion Criteria:

  • Intracranial hemorrhage
  • Pregnancy and other contraindication to MRI scan
  • Informed consent not obtained
  • Pre-existing medical, neurological or psychiatric disease that would confound the neurological, functional, or imaging evaluations
  • Known allergy to iodine previously refractory to pretreatment medications
  • Renal Failure (serum creatinine > 2.0 or Glomerular Filtration Rate [GFR] < 30)
  • History of sever kidney disease as an adult, including tumor or transplant surgery, or family history of kidney failure
  • Severe cardiac insufficiency

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Stroke
Ischemic stroke patients with sympton onset in 24 hours and no contradiction to MRI scan
MRI perfusion imaging, including contrast bolus perfusion imaging and arterial spin labeling.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
modified Rankin Score
Time Frame: Three months
Modified Rankin Score of patients with acute stroke after 3 months will be followed up for neurological outcome assessment. mRS < 2 is defined as favorable
Three months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Final infarct volume
Time Frame: Seven days to 1 month
Final infarct volume will be measured and infarct volume growth will be calculated.
Seven days to 1 month
Stroke event
Time Frame: within 1 year
The patients will be monitored whether they recured ischemic stroke event including transient ischemic attack (TIA) or stroke confirmed by neurologist and diffusion-weighted image MRI.
within 1 year
mortality
Time Frame: within 1 year
The patient will be monitored for death by telephone follow-up for neurological outcome assessment
within 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2015

Primary Completion (Actual)

December 31, 2020

Study Completion (Actual)

March 31, 2021

Study Registration Dates

First Submitted

October 16, 2015

First Submitted That Met QC Criteria

October 16, 2015

First Posted (Estimate)

October 20, 2015

Study Record Updates

Last Update Posted (Actual)

September 1, 2021

Last Update Submitted That Met QC Criteria

August 26, 2021

Last Verified

August 1, 2021

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on MRI

Subscribe